Charcot-Marie-Tooth Disease, Type IA
8
1
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Biomarkers and Validation of Selected Outcome Measures (CMTBiomarker)
Quantification of Nerve Stiffness in Neuropathies
Natural History Study for Charcot Marie Tooth Disease
Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A
Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A
Muscle MRI in Charcot Mary Tooth Disease: a Prospective Cohort Study
BALTiC Study: A Feasibility Analysis of Home Based BALance Training in People With Charcot-Marie-Tooth Disease
High Dose Ascorbic Acid Treatment of CMT1A